Learn more about World Kidney Day supporters
Our supporters are key in achieving the campaign mission of raising awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. We recognize their own initiatives in patient advocacy and care.
Find additional resources and learn more about each official World Kidney Day supporter by clicking on their name:
Additional resources will be made available here soon
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Specific to renal, we have partnered with the nephrology community to focus on pioneering care in both hemodialysis (HD) and peritoneal dialysis (PD); and we maintain that pioneering spirit today through new therapies like expanded hemodialysis (HDx) and remote patient management.
About Bayer’s Commitment in Cardiovascular and Kidney Diseases
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
Find more information at www.ckd-info.com
Follow us on Twitter: @KidneyDiseaseFm
Follow us on Facebook: https://www.facebook.com/KidneyDiseaseForum/
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network more than 4,150 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.
For more information, please visit https://www.veratx.com
IgAN patient stories:
Faces of IgA Nephropathy: Meet 3 patients living with IgAN
LinkedIn – https://www.linkedin.com/company/veratx/
Twitter – https://twitter.com/veratx2
How to become a World Kidney Day supporter
World Kidney Day is celebrated every year on the second Thursday of March. The WKD campaign is only possible thanks to the support of our global supporters.
View support brochure
As an official supporter, you will be:
- Officially associated with the WKD campaign as a supporter
- Able to use the WKD campaign logo along with communication materials such as template press releases, boiler plates and regular updates
- Able to participate in various additional partner activities, as proposed by the WKD team, throughout the year
- Be acknowledged as an official supporter of WKD campaign on various platforms, which includes, but are not limited to:
- World Kidney Day website
- ISN website
- Social media
- Campaign materials (Printed and online)
- Communications (Printed and online)
- Participation in quarterly calls with central campaign team for updates on campaign and strategy, help build communication and share information
- Able to use digital campaign materials for internal and external use
- Provided opportunities to share own resources, through official campaign channels, which are patient-focused or education/awareness-building, free of branding and products (agnostic), and approved by campaign team
To become a World Kidney Day supporter, please contact:
Charleigh Claire, Business Development Manager
World Kidney Day (WKD) is a global awareness campaign aimed at raising awareness about the importance of our kidneys. WKD is a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations(IFKF) who, together, generate WKD campaign content, educational material and activities. The annual campaign is overseen by the WKD Steering Committee composed of nephrology and transplantation experts who live and work in Africa, Asia, Australia, Europe, South America and North America. Financial support is solicited with the sole purpose of carrying out the campaign’s core activities and achieving campaign objectives. Our supporters provide financial support to carry out our activities, help us disseminate our message and strengthen our efforts, which WKD is very grateful for. However, supporters do not take part in any of the decision making and do not influence any of the content or messages disseminated by WKD.
The resources on this page are third party and content responsibility lies with owners of the material.